Target intelligence / Profile preview

Neisseria meningitidis serogroup C capsular polysaccharide antigen

Molecular classification
Bacterial polysaccharide antigen, Pathogen-associated molecular pattern (PAMP), Vaccine antigen, Other
01

Overview

The **Neisseria meningitidis serogroup C capsular polysaccharide antigen** is a high-molecular-weight, surface-exposed carbohydrate polymer that forms the outer capsule of *Neisseria meningitidis* serogroup C. This capsule is composed of repetitive units of sialic acid residues (specifically, α(2→9)-linked N-acetylneuraminic acid)[3]. It is the principal virulence factor enabling the bacterium to evade host immune responses by inhibiting complement-mediated killing and phagocytosis, which is critical for survival in the bloodstream and for pathogenesis. Antibodies generated against this polysaccharide provide protective immunity, and the antigen constitutes the basis for licensed polysaccharide and conjugate vaccines targeting serogroup C. The conjugate form (linked to carrier protein) is especially effective, as it induces long-lasting, robust immunity with immunological memory, including in infants—a key population at risk[3][4]. **Note:** The submitted target name was accurate but imprecise in format; the scientifically standard designation is “Neisseria meningitidis serogroup C capsular polysaccharide antigen”[3][4]. It is recognized as a distinct and well-validated vaccine and diagnostic antigen.

Other names
Neisseria meningitidis serogroup C polysaccharideNmC polysaccharideMeningococcal group C polysaccharideSerogroup C capsule antigen
02

Mechanism of action

Induction of antibody-mediated immunity via recognition of capsular polysaccharide as a T-cell–independent antigen (in plain polysaccharide vaccines)[3][4] Induction of T-cell–dependent immune response when conjugated to carrier proteins, resulting in immunological memory and robust protection (in conjugate vaccines)[3][4]

03

Biological functions

Immune evasionInduction of adaptive immune responseVirulence factorOther
04

Disease associations

InfectionMeningococcal disease (meningitis, sepsis)Other
05

Safety considerations

Hyporesponsiveness with repeated doses of plain polysaccharide vaccineRare risk of allergic reactions to vaccine formulationsLimited immunogenicity in infants with plain polysaccharide (non-conjugate) vaccines
06

Interacting drugs

Meningococcal group C polysaccharide vaccine

1 more in the full profile.

07

Biomarkers

Serum bactericidal antibody titer to serogroup C polysaccharideImmunoglobulin G (IgG) concentration specific for group C polysaccharide

Beyond the preview

Go deeper on Neisseria meningitidis serogroup C capsular polysaccharide antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisseria meningitidis serogroup C capsular polysaccharide antigen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call